Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase I Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Imago BioSciences, Inc. announced that the first participant had been dosed in an investigator-sponsored Phase I study of bomedemstat, an investigational oral lysine-specific demethylase 1 inhibitor, in combination with venetoclax (Venclexa®) in patients with relapsed or refractory AML.